Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

ASCO Statement Opposes Trump’s Recommended Budget Cuts to NIH

March 24, 2017
By Leah Lawrence
Article

ASCO has released a statement announcing its opposition to President Trump’s budget outline for FY2018, which would cut about $6 billion in funding to the National Institutes of Health.

American Society of Clinical Oncology (ASCO) President Daniel F. Hayes, MD, FACP, FASCO, recently released a statement announcing ASCO’s opposition to President Trump’s budget outline for FY2018, which would cut about $6 billion in funding to the National Institutes of Health (NIH). The Institute’s funding was approximately $32.3 billion for FY2016; this cut would reduce the organization’s funding by almost 20%.

“When we are on the cusp of tremendous advances in cancer care, the United States can’t turn back the clock on research that will benefit millions of Americans with life-threatening diseases and their families,” Hayes wrote in the statement. “ASCO urges Congress to reject the proposed cuts and increase federal support for the NIH and the National Cancer Institute.”

President Trump released his budget outline, “America First: A Budget Blueprint to Make America Great Again” on March 16. Among the proposed cuts to the Federal budget is a reduction in NIH spending by $5.8 billion. The proposal would also include a “major reorganization of NIH’s Institutes and Centers to help focus resources on the highest priority research and training activities.”

In his last year in office, President Obama proposed a FY2017 budget of $33.136 billion for the NIH, an amount the NIH Director Francis S. Collins, MD, PhD, said reflects a “dedication to improving the health and wellness of all Americans,” and would allow the Institutes to “remain on the cutting edge of scientific breakthroughs.”

According to the NIH, more than 80% of its funding is awarded through almost 50,000 competitive grants to more than 300,000 researchers at more than 2,500 universities, medical schools, and research institutions in the United States and around the world.

In his statement, Hayes wrote that in addition to rejecting President Trump’s proposed budget cuts for the NIH, ASCO urges Congress to continue the proposed FY2017 budget trajectory by significantly increasing funding for the NIH in FY2018.

“Now is not the time to slow progress in finding new treatments and cures for patients with cancer,” Hayes wrote. “In fact, after more than a decade of flat funding, our nation’s biomedical research infrastructure must catch up with sustained increases in future years to meet the possibility of today’s science.”

In the statement, ASCO encouraged its member to visit the ACT Network to contact their representative in Congress about this issue.

Recent Videos
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Advertisement

Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.

DB-1310 Earns FDA Fast Track Designation in EGFR-Mutant Nonsquamous NSCLC

Roman Fabbricatore
July 23rd 2025
Article

Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Subcutaneous Daratumumab Approved by EC in Smoldering Multiple Myeloma

Subcutaneous Daratumumab Approved by EC in Smoldering Multiple Myeloma

Ariana Pelosci
July 23rd 2025
Article

Results from the AQUILA trial led to the approval of subcutaneous daratumumab for patients with smoldering multiple myeloma at risk of developing the disease.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

European Commission Grants Marketing Authorization to Obe-Cel in R/R B-ALL

Tim Cortese
July 23rd 2025
Article

Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.


The SCIB1/iSCIB1+ cancer vaccines plus nivolumab and ipilimumab improved responses vs nivolumab and ipilimumab alone in patients with melanoma.

Novel Cancer Vaccine Combos Show Efficacy, Safety in Late-Stage Melanoma

Tim Cortese
July 22nd 2025
Article

The SCIB1/iSCIB1+ cancer vaccines plus nivolumab and ipilimumab improved responses vs nivolumab and ipilimumab alone in patients with melanoma.

Related Content
Advertisement

Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.

DB-1310 Earns FDA Fast Track Designation in EGFR-Mutant Nonsquamous NSCLC

Roman Fabbricatore
July 23rd 2025
Article

Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Subcutaneous Daratumumab Approved by EC in Smoldering Multiple Myeloma

Subcutaneous Daratumumab Approved by EC in Smoldering Multiple Myeloma

Ariana Pelosci
July 23rd 2025
Article

Results from the AQUILA trial led to the approval of subcutaneous daratumumab for patients with smoldering multiple myeloma at risk of developing the disease.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

European Commission Grants Marketing Authorization to Obe-Cel in R/R B-ALL

Tim Cortese
July 23rd 2025
Article

Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.


The SCIB1/iSCIB1+ cancer vaccines plus nivolumab and ipilimumab improved responses vs nivolumab and ipilimumab alone in patients with melanoma.

Novel Cancer Vaccine Combos Show Efficacy, Safety in Late-Stage Melanoma

Tim Cortese
July 22nd 2025
Article

The SCIB1/iSCIB1+ cancer vaccines plus nivolumab and ipilimumab improved responses vs nivolumab and ipilimumab alone in patients with melanoma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.